Exact Sciences Corp Q2 2023 Earnings Call Summary - Thomson StreetEvents

Exact Sciences Corp Q2 2023 Earnings Call Summary

Exact Sciences Corp Q2 2023 Earnings Call Summary - Thomson StreetEvents
Exact Sciences Corp Q2 2023 Earnings Call Summary
Published Aug 01, 2023
16 pages (9565 words) — Published Aug 01, 2023
Price US$ 54.00  |  Buy this Report Now

About This Report

  
Abstract:

Edited Brief of EXAS.OQ earnings conference call or presentation 1-Aug-23 9:00pm GMT

  
Brief Excerpt:

...A. We made significant progress toward our mission to eradicate cancer during the second quarter, including being Great Place to Work certified for the fifth consecutive year, delivering more than 1 million test results to patients generating core revenue of $617 million, an improvement of $119 million year-over-year with an 18% decline in sales and marketing expense. B. Producing $66 million of free cash flow, a $190 million improvement announcing positive top line results from our BLUE-C study, in which our next-generation Cologuard test exceeded our expectations for improved sensitivity and specificity, securing reimbursement for the Oncotype DX test in Japan and initiating collaborations with the Broad Institute to support our molecular residual disease test platform and Baylor Scott & White to support our Multicancer Early Detection program. C. As a result of the outstanding results in the second quarter, we're raising our full year guidance for revenue by $54 million and adjusted...

  
Report Type:

Brief

Source:
Thomson StreetEvents
Company:
Exact Sciences Corp
Ticker
EXAS.OQ
Time
9:00pm GMT
Format:
PDF Adobe Acrobat
Buy Now

The following is excerpted from the question-and-answer section of the transcript.

(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)

Question: Kyle Alexander Mikson - Canaccord Genuity Corp., Research Division - Analyst : I want to go back to the financials and the model really, Jeff, can you kind of walk through market implications of this $50 million COVID headwind to rescreen revenue in the second half? I guess like for context, you're guiding to a mid-single-digit adjusted EBITDA margin in the second half. That makes sense given the rescreening revenue is higher margin when that headwind lifts in the first half of next year, you would think that margins would bounce back. But that's kind of in line with how you talk about pushing margins higher over time. But you have other studies coming up in '24 and beyond. So I guess just wrapping this up, how do we kind of think about the margin profile going forward in the context of all these different pieces?

Table Of Contents

Exact Sciences Corp at Stifel Healthcare Conference Transcript – 2023-11-14 – US$ 54.00 – Edited Transcript of EXAS.OQ presentation 14-Nov-23 3:20pm GMT

Exact Sciences Corp Q3 2023 Earnings Call Summary – 2023-11-01 – US$ 54.00 – Edited Brief of EXAS.OQ earnings conference call or presentation 1-Nov-23 9:00pm GMT

Exact Sciences Corp Q3 2023 Earnings Call Transcript – 2023-11-01 – US$ 54.00 – Edited Transcript of EXAS.OQ earnings conference call or presentation 1-Nov-23 9:00pm GMT

Exact Sciences Corp at Robert W Baird Global Healthcare Conference Transcript – 2023-09-12 – US$ 54.00 – Edited Transcript of EXAS.OQ presentation 12-Sep-23 2:50pm GMT

Exact Sciences Corp Q2 2023 Earnings Call Transcript – 2023-08-01 – US$ 54.00 – Edited Transcript of EXAS.OQ earnings conference call or presentation 1-Aug-23 9:00pm GMT

Exact Sciences Corp at Goldman Sachs Healthcare Conference Summary – 2023-06-13 – US$ 54.00 – Edited Brief of EXAS.OQ presentation 13-Jun-23 8:20pm GMT

Exact Sciences Corp at Goldman Sachs Healthcare Conference Transcript – 2023-06-13 – US$ 54.00 – Edited Transcript of EXAS.OQ presentation 13-Jun-23 8:20pm GMT

Exact Sciences Corp at William Blair Growth Stock Conference Summary – 2023-06-07 – US$ 54.00 – Edited Brief of EXAS.OQ presentation 7-Jun-23 8:20pm GMT

Exact Sciences Corp at Jefferies Healthcare Conference Summary – 2023-06-07 – US$ 54.00 – Edited Brief of EXAS.OQ presentation 7-Jun-23 6:00pm GMT

Exact Sciences Corp at William Blair Growth Stock Conference Transcript – 2023-06-07 – US$ 54.00 – Edited Transcript of EXAS.OQ presentation 7-Jun-23 8:20pm GMT

More from Thomson StreetEvents

Thomson StreetEvents—Thomson StreetEvents is a leading provider of Web-based solutions for the investment community, offering services that transform the way companies communicate and meet disclosure requirements while assisting investors in managing and leveraging this information. Thomson StreetEvents service offers institutional investors a one-stop solution for managing corporate disclosure information by aggregating conference calls, webcasts, transcripts, call summaries, and other financial information into a time-saving, efficiency tool.
Purchase Thomson StreetEvents' Transcripts (verbatim reports) and Briefs (call summaries) of earnings, guidance, M&A and other corporate calls directly through Alacra. Discounted prices apply to reports produced over two weeks ago.

About the Author


Cite this Report

  
MLA:
Thomson StreetEvents. "Exact Sciences Corp Q2 2023 Earnings Call Summary" Aug 01, 2023. Alacra Store. May 17, 2025. <http://www.alacrastore.com/thomson-streetevents-transcripts/Q2-2023-Exact-Sciences-Corp-Earnings-Call-B15656859>
  
APA:
Thomson StreetEvents. (2023). Exact Sciences Corp Q2 2023 Earnings Call Summary Aug 01, 2023. New York, NY: Alacra Store. Retrieved May 17, 2025 from <http://www.alacrastore.com/thomson-streetevents-transcripts/Q2-2023-Exact-Sciences-Corp-Earnings-Call-B15656859>
  
US$ 54.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Credit Research from one place.